Kiadis Pharma N.V.(ENXTAM:KDS) dropped from Next Biotech Index

Kiadis Pharma NV is a biopharmaceutical company based in the Netherlands. It focuses on development of therapies for patients with life-threatening diseases. Its programs consist of off-the-shelf and haploidentical donor NK-cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies. Its PM21 particle technology enables ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions. Its off-the-shelf NK-cell platform is based on NK cells from unique universal donors and can make NK-cell therapy product available for a broad patient population across a potentially wide range of indications. It develops K-NK003 for the treatment of relapse/refractory acute myeloid leukemia, and K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT. In addition, it has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors. It has offices in the United States and Europe.